One cell type may quash tumor vaccines

April 28, 2014

Most cancer vaccines have not lived up to their promise in clinical trials. The reason, many researchers suspect, is that the immune cells that would help the body destroy the tumor – even those reactions boosted by cancer vaccines – are actively suppressed. Now, researchers at Thomas Jefferson University have found that a single cell type is actively suppressed in several experimental cancer vaccines, paving the way toward methods to break suppression and improve the effectiveness of cancer vaccines. The work was published this week online in the European Journal of Immunology.

"The conventional wisdom is that the body knocks out all of the cells that can mount an to the cancer," says first author Adam Snook, PhD, a Research Instructor at Thomas Jefferson University. "In fact, our work shows that it's only one cell type that is affected. But that cell, the T-helper cell, acts as the lynchpin."

Cancer vaccines are designed to boost the body's natural defenses against cancer. They work by training the immune system to recognize and attack specific tumor peptides, which are a kind of identification tag for tumors. These peptide "tags" help the immune system find and attack cancer cells. There are three types of cells that can "see" and react to these tags: T-helper cells, cytotoxic T cells, and B cells, and researchers thought that all three were trained, or tolerized, to ignore the tags on cancer cells.

Dr. Snook and colleagues tested which cell was involved by inoculating mice with a cancer vaccine they developed for colorectal cancer using a tumor peptide called guanylyl cyclase C (GUCY2C). Normally, GUCY2C-vaccinated mice would not produce much of an immune response, from either T cell type or B cells. However, when the researchers boosted the GUCY2C vaccine by linking it to another peptide called S1 that efficiently activates T-helper cells, they were able to see a vigorous activation of cytotoxic T cells and B cells directed at GUCY2C.

In fact, the GUCY2C vaccine-S1 combo improved the survival time of mice with cancer by months compared to only days with GUCY2C vaccine alone. In fact, many mice were cured of their disease.

When Dr. Snook tested two other cancer peptides, one for breast cancer (Her2) and one for melanoma (Trp2), he saw similar results, suggesting that selective inactivation of T helper cells occurs for peptides found in many cancer types. "The results make a lot of sense," says Dr. Snook. "T-, as their name suggests, provide help to both cytotoxic T cells and to B cells. The entire peptide-specific immune response can be taken out by tolerizing this one cell type."

In addition, T-helper are also essential for creating immunological memory. Boosting T-helper cell activation also protected mice from challenge with cancer months after the initial vaccination, increasing their survival and decreasing tumor number.

The next step is to test whether a T helper peptide-linked GUCY2C vaccine could help fight colorectal cancer in humans. Dr. Snook and colleagues are currently enrolling patients in a clinical trial aimed at reducing the rate of recurrence in patients who had their primary tumors removed.

Explore further: Radiation therapy and cancer vaccines: Timing is everything

More information: AE Snook, et al., "Self-tolerance eliminates CD4+ T, but not CD8+ T or B, cells corrupting cancer immunotherapy," European Journal of Immunology, DOI: 10.1002/eji.201444539, 2014.

Related Stories

Radiation therapy and cancer vaccines: Timing is everything

March 24, 2014
Radiation therapy fights cancer in more ways than one. Not only does it force cancer cells to self-destruct, but several studies demonstrate that it also activates the immune system to attack tumor cells. This activation ...

Protein serves as a natural boost for immune system fight against tumors

January 30, 2014
Substances called adjuvants that enhance the body's immune response are critical to getting the most out of vaccines. These boosters stimulate the regular production of antibodies—caused by foreign substances in the body—toxins, ...

Cancer vaccine could use immune system to fight tumors

February 27, 2014
Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune ...

Cancer vaccine a step closer as natural killer cells are rightly activated

March 25, 2014
Vaccines work. Their widespread use has saved millions of lives. With an ageing population that is increasingly becoming a victim to cancer, a vaccine to treat it would do wonders. In a study published in Nature, scientists ...

Enzyme revealed as promising target to treat asthma and cancer

April 10, 2014
In experiments with mice, Johns Hopkins Kimmel Cancer Center scientists have identified an enzyme involved in the regulation of immune system T cells that could be a useful target in treating asthma and boosting the effects ...

Bacteria may assist the immune system response against cancer

March 3, 2014
(Medical Xpress)—Recent research from the University of Otago shows that bacteria may assist the body's immune system response against cancer cells and help fight tumours like melanoma.

Recommended for you

Genetic immune deficiency could hold key to severe childhood infections

July 18, 2017
A gene mutation making young children extremely vulnerable to common viruses may represent a new type of immunodeficiency, according to a University of Queensland researcher.

What are the best ways to diagnose and manage asthma?

July 18, 2017
What are the best ways to diagnose and manage asthma in adults? This can be tricky because asthma can stem from several causes and treatment often depends on what is triggering the asthma.

Study finds molecular explanation for struggles of obese asthmatics

July 17, 2017
A large, bouquet-shaped molecule called surfactant protein A, or SP-A, may explain why obese asthma patients have harder-to-treat symptoms than their lean and overweight counterparts, according to a new study led by scientists ...

Large multi-ethnic study identifies many new genetic markers for lupus

July 17, 2017
Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus.

Team identifies potential cause for lupus

July 14, 2017
Leading rheumatologist and Feinstein Institute for Medical Research Professor Betty Diamond, MD, may have identified a protein as a cause for the adverse reaction of the immune system in patients suffering from lupus. A better ...

Immunosuppression underlies resistance to anti-angiogenic therapy

July 14, 2017
A Massachusetts General Hospital (MGH) research team has identified a novel mechanism behind resistance to angiogenesis inhibitors - drugs that fight cancer by suppressing the formation of new blood vessels. In their report ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.